Monday, 20 Feb 2017

Today's Headlines

The RheumNow Week in Review – 17 February 2017

Dr. Jack Cush reviews this week's news and information from the 2017 RWCS meeting in Maui.

BEAM Study: Baricitinib Beats Placebo and Adalimumab in Rheumatoid Arthritis

Baricitinib is a novel inhibitor of Janus kinases JAK1 and JAK2 that has been extensively studied in rheumatoid arthritis (RA).  Baricitinib (AKA Oluminant) was recently approved by the EMA for use in Europe at a once daily dose of 4 mg per day.  Regulatory approval in the USA is pending with the FDA.

Top Ten Things Rheumatologists Should Know When Ordering Imaging

As a musculoskeletal radiologist, I work every day with rheumatologists. I have been in practice for approximately 17 years and had a musculoskeletal radiology fellowship prior to establishing my practice. I greatly enjoy working with rheumatologists and their patients and, like you, want to get the most out of the imaging studies you order.

As such, here are my top ten things every rheumatologist should know when ordering imaging:

Valeants Brodalumab FDA Approved for Psoriasis

FDA has approvesd the IL-17 targeted therapy Siliq (brodalumab) for moderate-severe plaque psoriasis.

The drug was originally developed by Amgen and Astra-Zenica but they abandoned its development with concerns about depression and risk of suicide.  The agent was purchased by Valeant and brought to market, but not without some concernes.  Notably the agent comes with a black box warning for suicide.

Baricitinib Approved in the EU for Use in Rheumatoid Arthritis

The European Commission has approved Eli Lilly's rheumatoid arthritis drug Olumiant (baricitinib) for use in Europe for RA patients with moderate-to-severe active disease in adults who have not responded one or more disease-modifying antirheumatic drugs.
BLOG

This is going to be my third visit with this patient and I’m not looking forward to it.

In the years to come, the availability of numerous new IL-6 inhibitors it will either complicate treatment decisions, alter existing treatment paradigms, or result in an all-out war against TNF inhibitor dominance. Data, differences and time will tell.

Recently, I went to one of my patient’s funeral. It was sad.

I got onto flight #610 from Atlanta to Dallas the other day and was greeted by a flight attendant in first class. After introducing himself, he said, “That’s my name and you can imagine how it’s gone for the past 25 years.”
I’m sitting with a patient discussing moving to an advanced therapeutic (i.e., medication that costs a lot of money). I started thinking about what I would choose and given my busy lifestyle a quick injection or tablet would seem preferable to an intravenous infusion. I assume that my patients are probably like me and would make similar choices. I am a little taken aback when this patient chooses an IV medication. She tells me her rationale in terms of her feelings, ideas, fears, and expectations and it makes complete sense. I may have misjudged her and without asking may have suggested a treatment that would not have been the best for her in terms of her lifestyle or beliefs.
Dr. Olga Petryna: Cardiovascular risk and Takayasu's arteritis
Dr. Petryna discusses a retrospective study on cardiovascular event risk for patients with Takayasu's arteritis presented at the ACR/ARHP Annual Scientific Meeting.
/vef/load/dbc7fde3081dc825d28f41f348810282?width=640&height=365

Daily Download

Future Biologic Patent Expirations

RheumNow Live Vote

With MTX, what dose/schedule of folate do you use?

This month’s Live Vote is being guided by Dr. Joel Kremer and will focus on methotrexate and folate issues.

View the Result